Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Anthropic co-founder Dario Amodei urges a deliberate slowdown in AI development, emphasizing ...

Yesterday (Sep 10) we had a test of key support in SPX in the 7565-7578 area. At the same time we had a timing histogram that suggested a possible low with the cycles coming in Sep 10-11. This told us ...

It’s the sunflower time of year, as the flowers spangle yards and roadsides and meadows in gold. But have you ever studied those gorgeous orbs up close? As sunflowers go to seed, the flower heads ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...

Recursion Pharmaceuticals leverages an artificial intelligence platform to decode biology and automate the drug discovery process. Summit Therapeutics is focused on its lead oncology candidate, ...

Recursive Superintelligence, a London and San Francisco-based artificial intelligence startup, has officially emerged from stealth with a $650 million Series A funding round. Founded in 2026, ...

Amazon MGM Studios is touting the power of AI to help create “cinematic” entertainment in a big new initiative — although execs are quick to say it will empower human creative professionals, not ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...